يعرض 101 - 110 نتائج من 253 نتيجة بحث عن '"Rugo H.S."', وقت الاستعلام: 0.92s تنقيح النتائج
  1. 101
    دورية أكاديمية
    Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours

    الإتاحة: https://doi.org/10.1093/annonc/mdz242.040Test
    https://api.elsevier.com/content/article/PII:S0923753419585672?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419585672?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz242.040/30082246/mdz242.040.pdfTest

    View record in BASE

    أضف إلى المفضلة
  2. 102
    دورية أكاديمية
    A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma

    الإتاحة: https://doi.org/10.1093/annonc/mdz198Test
    https://api.elsevier.com/content/article/PII:S0923753419459899?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419459899?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/9/1514/30092870/mdz198.pdfTest

    View record in BASE

    أضف إلى المفضلة
  3. 103
    دورية أكاديمية
    Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

    الإتاحة: https://doi.org/10.1093/annonc/mdy518Test
    https://api.elsevier.com/content/article/PII:S0923753419310762?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419310762?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/3/405/28255067/mdy518.pdfTest

    View record in BASE

    أضف إلى المفضلة
  4. 104
    دورية أكاديمية
    Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries

    الإتاحة: https://doi.org/10.1093/annonc/mdz418Test
    https://api.elsevier.com/content/article/PII:S092375341957733X?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S092375341957733X?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/Supplement_9/mdz418/31094524/mdz418.pdfTest

    View record in BASE

    أضف إلى المفضلة
  5. 105
    دورية أكاديمية
    PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIOR CHEMOTHERAPY (CT) SUBGROUPS

    الإتاحة: https://doi.org/10.1016/j.jval.2019.09.683Test
    https://api.elsevier.com/content/article/PII:S109830151933061X?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S109830151933061X?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  6. 106
    دورية أكاديمية
    Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial

    الإتاحة: https://doi.org/10.1093/annonc/mdz100.005Test
    https://api.elsevier.com/content/article/PII:S0923753419304223?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419304223?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/Supplement_3/mdz100.005/28601168/mdz100.005.pdfTest

    View record in BASE

    أضف إلى المفضلة
  7. 107
    دورية أكاديمية
    Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

    الإتاحة: https://doi.org/10.1093/annonc/mdz100.013Test
    https://api.elsevier.com/content/article/PII:S0923753419304302?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419304302?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/Supplement_3/mdz100.013/28600815/mdz100.013.pdfTest

    View record in BASE

    أضف إلى المفضلة
  8. 108
    دورية أكاديمية
    LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

    الإتاحة: https://doi.org/10.1093/annonc/mdy424.010Test
    https://www.openaccessrepository.it/record/45656Test

    View record in BASE

    أضف إلى المفضلة
  9. 109
    دورية أكاديمية
    4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

    الإتاحة: https://doi.org/10.1093/annonc/mdy192Test
    https://api.elsevier.com/content/article/PII:S0923753419341134?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419341134?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/29/8/1634/25505041/mdy192.pdfTest

    View record in BASE

    أضف إلى المفضلة
  10. 110
    دورية أكاديمية
    Reply to the letter to the editor ‘Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses’ by Kaiser et al.

    الإتاحة: https://doi.org/10.1093/annonc/mdy206Test
    https://api.elsevier.com/content/article/PII:S0923753419341274?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419341274?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/29/8/1878/25504987/mdy206.pdfTest

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث